The Daily Biotech Pulse: Limited Use Of JNJ’s COVID-19 Shot, Myovant-Pfizer’s Relugolix Application Delayed, Gain Therapeutics’ Parkinson’s Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Myovant, Pfizer Offer Update On Supplemental New Drug Application For MYFEMBREE For Mgmt. Of Moderate To Severe Pain Associated With Endometriosis: FDA Extended Review Period, New PDUFA Date Goal Is Aug. 6, 2022
Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE®
Here’s Why This Analyst Is On Sidelines Despite European Approval Of Myovant’s Relugolix For Prostate Cancer
Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think…
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a measure of innovation in drug research, tapered to merely one for the month.
Myovant Investment Sumitomo Pharma’s Urovant Sciences Highlights Publication Of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy Of GEMTESA In Dry, Wet Overactive Bladder Populations In ‘Int’l. Journal Of Clinical Practice’
Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB)
Article appears in the peer-reviewed
SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12
SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00.
Shares of Myovant Sciences are trading up 8.08% over the last 24 hours, at $11.23 per share.
SVB Leerink Maintains Market Perform on Myovant Sciences, Lowers Price Target to $12
SVB Leerink analyst Roanna Ruiz maintains Myovant Sciences (NYSE:MYOV) with a Market Perform and lowers the price target from $19 to $12.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers
Zosano Pharma (NASDAQ:ZSAN) shares rose 3127.9% to $3.88 during Tuesday's pre-market session. The market value of their outstanding shares is at $19.0 million.